NicOx.... in attesa di.....
- Creatore Discussione DickSIM
- Data di Inizio
PIZZODIGINO
Pacifico
Zohar
Forumer storico
viralic
Forumer storico
Consigli dalla regia approfittando dei ribassi generalizzati, alcuni decisamente motivati altri molto meno.........
Nektar ( nktr) quotata al nasdaq........un gioiello valutato in borsa 1600 milioni di dollari, con una pipeline unica.....che vi allego.........a dir poco spaventosamente sottovalutata....
Per farvi un esempio Keryx con un solo farmaco in fase III vale 1300 milioni di dollari........
Nektar | R&D Pipeline | Products in Development | Product Pipeline
Nektar ( nktr) quotata al nasdaq........un gioiello valutato in borsa 1600 milioni di dollari, con una pipeline unica.....che vi allego.........a dir poco spaventosamente sottovalutata....
Per farvi un esempio Keryx con un solo farmaco in fase III vale 1300 milioni di dollari........
Nektar | R&D Pipeline | Products in Development | Product Pipeline
Ultima modifica:
Zohar
Forumer storico
viralic
Forumer storico
Allora non sono proprio degli stinchi di santi ..........
03/02/14 | 15:40 | AstraZeneca under investigation for Brilinta FDA approval (AZN) - An adjunct medical professor at Johns Hopkins Hospital has challenged the FDA's 2011 approval of AstraZeneca's anticlotting drug Brilinta, the WSJ reports. Using the federal False Claims Act, Victor Serebruany has filed a complaint arguing that data was manipulated in a trial which showed that the medicine saved lives and cut heart attacks. The U.S. attorney's office in Washington DC is investigating the conduct of the trial. Separately, AstraZeneca (AZN) has completed the acquisition of Bristol-Myers Squibb's (BMY) holding in the companies' diabetes joint venture for an initial $2.7B and as much as $1.65B in additional payments, as well as royalties on sales.
03/02/14 | 15:40 | AstraZeneca under investigation for Brilinta FDA approval (AZN) - An adjunct medical professor at Johns Hopkins Hospital has challenged the FDA's 2011 approval of AstraZeneca's anticlotting drug Brilinta, the WSJ reports. Using the federal False Claims Act, Victor Serebruany has filed a complaint arguing that data was manipulated in a trial which showed that the medicine saved lives and cut heart attacks. The U.S. attorney's office in Washington DC is investigating the conduct of the trial. Separately, AstraZeneca (AZN) has completed the acquisition of Bristol-Myers Squibb's (BMY) holding in the companies' diabetes joint venture for an initial $2.7B and as much as $1.65B in additional payments, as well as royalties on sales.
Aeiou
▲ + 444%
PIZZODIGINO
Pacifico
Guly, hai visto che mazzate ieri la Molmed e la Keryx.
Davvero non c'è pace per le biotech.
Davvero non c'è pace per le biotech.
